Functional RNAi and CRISPR Screening and Drug Target & Biomarker Discovery
Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad-based screening and analysis approaches for drug target and biomarker discovery. Our high-throughput functional genetic screening portfolio includes:
- shRNA and CRISPR screening services
- custom and off-the-shelf pooled libraries
- knockout and knockdown cell lines
that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
With DriverMap™ Targeted Gene Expression Profiling Service, Cellecta offers a quantitative, multiplexed approach that allows simultaneous profiling of all human protein-coding genes in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
2018 American Association for Cancer Research (AACR) Annual Meeting, McCormick Place Convention Center, Chicago, IL, April 14-18, 2018. Register for our technology workshop. Stop by Booth # 2421.
2018 Association of Biomolecular Research Facilities (ABRF) Annual Meeting, Myrtle Beach Convention Center, Myrtle Beach, SC, April 22-25, 2018. Register for our technology workshop. Come see us at Booth # 411.
RNA-Seq Summit 2018, Le Meridien Hotel, San Francisco, CA, April 24-26.
With DriverMap, Cellecta offers a novel, comprehensive end-to-end service portfolio for identifying differential gene expression, mapping of clinically actionable mutations in RNA, detecting cellular composition, and profiling immunotherapy targets.
Cellecta, partnered with RPCI, FHCRC, and TSRI has created one of the most effective and published pooled shRNA library platforms available. We now also offer pooled premade and custom CRISPR libraries.
We’ll perform any or all steps, from RNAi and CRISPR screening to NGS to data analysis. Cellecta specializes in negative screens (i.e. viability or drop-out) to identify cancer drug targets.